PDCD1 and post-transplant lymphoproliferative disease: In one report, autologous anti-CD19 CAR T-cells were combined with immune checkpoint blockade (anti-programmed cell death-1 [PD-1] antibody) in a PTLD patient with a prior allogeneic kidney transplant [69].